Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

602P - Application of low-power intermittent microwave ablation in treating early-stage lung cancer lesions

Date

07 Dec 2024

Session

Poster Display session

Presenters

Wangrui Liu

Citation

Annals of Oncology (2024) 35 (suppl_4): S1616-S1622. 10.1016/annonc/annonc1696

Authors

W. Liu

Author affiliations

  • Thoracic Surgery Dept., Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200127 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 602P

Background

This study aims to evaluate the efficacy and safety of low-power intermittent microwave ablation (MWA) in treating ground-glass nodules (GGOs) in early-stage lung cancer. It also seeks to compare the outcomes with those of high-power MWA, highlighting the potential benefits of a lower power approach in minimizing complications.

Methods

A retrospective analysis was conducted on 131 GGO cases treated with low-power intermittent MWA (40W) from January 2019 to December 2022. These results were compared with patients treated with high-power MWA (>60W) during the same period. The effectiveness of MWA was assessed by evaluating changes in lesion size and absorption rates post-procedure. Additionally, postoperative complications were systematically recorded and analyzed to compare the safety profiles of the two approaches.

Results

The success rate of nodule ablation with low-power MWA was 100%, with NADH staining confirming complete cell death in the target area. Lesion size significantly reduced 24 hours post-procedure (p<0.001), with an overall absorption rate of 80.2% at three months. In contrast, high-power MWA, although effective, had a higher complication rate, including large pneumothorax (11.4%) and excessive lung tissue damage. Complications from low-power MWA were milder and more manageable, with minor pneumothorax (58.0%) and pleural indentation (39.7%) being the main issues.

Conclusions

The study concludes that low-power intermittent MWA at 40W is highly effective and safe for eliminating GGO nodules, offering significant advantages in terms of fewer complications and better patient tolerance compared to high-power MWA. Low-power intermittent MWA emerges as a safe and effective treatment option for early-stage lung cancer patients, providing a favorable balance between efficacy and safety.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.